[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:melanoma:nf1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Melanoma","NF1 Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07237100","Mirdametinib in Patients With Advanced NF1-mutant Melanoma",[12],"Phase 2","RECRUITING","2026-08-26T02:17:41.695983Z","2026-05-05T02:43:29.510066Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07252479","Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations",[20],"Phase 1","2026-08-26T02:16:01.910993Z","2026-06-16T05:54:07.937487Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05039801","IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors",[20],"2026-08-26T02:18:49.989941Z","2026-04-29T02:57:57.070174Z"]